- The Tamro Group's hospital and laboratory division is expanding in the Nordic countries and growing in the pharmaceutical distribution area. The recent acquisition of Helgar & Co A/S, a Norwegian company, has strengthened the position of the Tamro group Swedish AB Labassco unit. Labassco bought all Helgar & Co's capital stock, whose laboratory products market share in Norway is nearly 10%. Meantime, Tamro's joint-venture company based in St Petersburg, Pharm Tamda 77, has opened a new bonded warehouse and a distribution warehouse in the city.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze